Interstitial Lung Disease Induced by Drugs and Radiation

Abstract

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by the meticulous exclusion of all other possible causes. Drug dechallenge produces measurable improvement in symptoms and imaging in the majority of patients, whereas corticosteroid therapy is indicated if symptoms are present or drug dechallenge is without an effect. Rechallenge is justified in a minority of patients, and is discouraged for diagnostic purposes only. Pneumotox^® (www.pneumotox.com) provides updated information on drug-induced respiratory disease.

Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis

“…This is cause for serious clinical concern, as it can lead to patient death, thereby restricting the therapeutic use of these drugs. [3][4][5] Unfortunately, the etiology of drug-induced ILD (pulmonary fibrosis) is not yet understood and, as a result, an appropriate animal model has not yet been established. Although the bleomycin-induced pulmonary fibrosis animal model mimics some characteristics of human pulmonary fibrosis, 6 it remains unclear whether drugs known to induce ILD clinically exacerbate bleomycin-induced effects.…”

Chronic Eosinophilic Pneumonia in a Breast Cancer Patient Post-Radiation Therapy: A Case Report

“…13 They had a median presentation of symptoms 3.5 months after completion of radiation therapy. 1,14 Our patient met all criteria for the diagnosis of CEP; however, she presented 6 years after completion of her radiation therapy.…”

Life-threatening interstitial lung disease associated with trastuzumab: case report

“…Early withdrawal of the causative drug will often lead to improvement or even cure of the ILD. Corticosteroids may suppress the inflammatory reaction [10,11].…”